Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Perjeta, The Cost Of HER2 Breast Cancer Therapy Goes Up

Executive Summary

Roche’s Perjeta will be priced at a premium to Herceptin and used in combination with it, more than doubling the cost of treating patients with HER2-positive metastatic breast cancer.

You may also be interested in...



Big Data’s Day Will Dawn Despite Big Questions, Experts Say

The complexity of molecular datasets and issues around their use, like cost, are enormous challenges in oncology applications, but not insurmountable, leaders at the Cancer Progress conference say.

Kadcyla Positioned For Wide Use In Metastatic Breast Cancer

Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line+ mBC, but labeling allows first-line treatment in a subset of patients at high risk.

Kadcyla Positioned For Wide Use In Metastatic Breast Cancer

Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line HER-2 positive mBC, but labeling allows first-line treatment in a subset of patients at high risk.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel